CAI · Caris Life Sciences Inc
Snapshot
50 fields · last close| Market Cap | $8.35B |
| P/E | 79.37 |
| Float | 124.5M |
| Beta | 0.40 |
| Volatility | 9.9% |
| Exchange | NASDAQ |
| Sector | Biotechnology |
| Cap tier | Mid cap |
| Macro sensitivity | Low |
| Clavix score | 57.5 |
| Price | 30.52 |
| Change | +3.35% |
| Prev Close | 29.53 |
| Open | 29.48 |
| Day Low | 28.66 |
| Day High | 29.78 |
| Avg Vol | 4 |
| Avg $ Vol | $126.2M |
| 52W High | 33.65 |
| 52W Low | 14.19 |
| 52W Pos | 83.9% |
| From High | −9.30% |
| From Low | +115.08% |
| Max DD 1Y | — |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | — |
| SMA 50 | — |
| SMA 200 | — |
| RSI (14) | — |
| Vol 30D | — |
| Vol 90D | — |
| 1Y Range | 14–34 |
| Daily bars | — |
| Perf Week | — |
| Perf Month | — |
| Perf Quarter | — |
| Perf Half Y | — |
| Perf Year | — |
| Perf YTD | — |
| Prev Day | +3.35% |
| Clavix | C |
| Debt / Eq | 0.66 |
| Curr Ratio | 7.85 |
| Int Cover | 6.0× |
| FCF Margin | 8.2% |
| Rev Growth | +97.0% |
| Profit | Unprofitable |
| Leverage | Low |
| Sector rank | 28 / 35 |
Clavix risk grade
regraded every trading dayCAI grades C, 57.5 of 100. Steadiest on News Sentiment (68), most exposed on Price Stability (34, weak). 1 of the 4 weighted dimensions sit above the Biotechnology median. Ranks 28 of 35 in Biotechnology by Clavix score.
How rough the ride is
| CAI | Biotechnology median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 0.40 | 0.50 |
| Volatilityannualized | 9.9% | 14.4% |
| Max drawdown, past yearworst peak-to-trough fall | — | — |
| Typical daily movemedian absolute daily change | — | — |
| Days beyond ±3%of the last 0 sessions | — | — |
Market sensitivity
| CAI | Biotechnology median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 0.40 | 0.50 |
| Macro sensitivityrate, dollar and credit exposure bucket | Low | Low 53% of 36 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Biotechnology names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| CAI | |
|---|---|
| 1 week | — |
| 1 month | — |
| Year to date | — |
| 1 year | — |
Context for the rank, not itself a risk measure.
No scored coverage for CAI in the recent pool.
Balance sheet, against the sector
The shaded band is the middle half of the 36 Biotechnology names Clavix covers; the tick is the sector median.
Growth
| CAI | |
|---|---|
| Revenue growthyear over year | +97.0% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Biotechnology median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Nearest peers by size
Biotechnology| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| TGTX | TG Therapeutics Inc | B- | $8.32B | 19.16 | 1.82 | Compare |
| ARWR | Arrowhead Pharmaceuticals Inc | C+ | $8.21B | — | 1.33 | Compare |
| CYTK | Cytokinetics Inc | B+ | $8.57B | — | 0.41 | Compare |
| SYRE | Spyre Therapeutics Inc | — | $8.87B | — | 2.95 | Compare |
| PTGX | Protagonist Therapeutics Inc | B | $8.96B | 108.03 | 1.19 | Compare |
| KRYS | Krystal Biotech Inc | B | $9.51B | 39.71 | 0.64 | Compare |
| IONS | Ionis Pharmaceuticals Inc | B- | $7.04B | — | 0.38 | Compare |
| TWST | Twist Bioscience Corp | D+ | $9.96B | — | 2.15 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. Three months free on iPhone.